ADPT — Adaptive Biotechnologies Share News
0.000.00%
Last trade - 00:00- $4.08bn
- $4.08bn
- $276.98m
U.S. RESEARCH ROUNDUP-Albemarle, Cable One, Southwest Airlines
Adaptive Biotechnologies Corp reports results for the quarter ended in March - Earnings Summary
Brief: Adaptive Biotechnologies Reports First Quarter 2023 Financial Results
Brief: Adaptive Biotechnologies Reports First Quarter 2023 Financial Results
Adaptive Biotechnologies Corp expected to post a loss of 38 cents a share - Earnings Preview
Brief: Adaptive Biotechnologies Announces Translational Collaboration With Takeda To Measure Minimal Residual Disease With Its Clonoseq Assay Across Its Hematologic Malignancy Pipeline
Adaptive Biotechnologies Corp reports results for the quarter ended in December - Earnings Summary
Brief: Adaptive Biotechnologies Reports Fourth Quarter Results
Brief: Adaptive Biotechnologies Reports Fourth Quarter 2022 Results, Provides 2023 Outlook
Adaptive Biotechnologies Corp expected to post a loss of 35 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Apollo Global Management, Microsoft, ServiceNow
U.S. STOCKS ON THE MOVE-Nike, Venus Concept, Zymeworks
U.S. STOCKS ON THE MOVE-Nike, Venus Concept, Core Scientific, Zymeworks
U.S. STOCKS ON THE MOVE-Tesla, Nike, Zynerba Pharmaceuticals
U.S. STOCKS ON THE MOVE-Tesla, Nike, Starbucks, Core Scientific
Piper Sandler upgrades Adaptive Biotech on diagnostics strength
Brief: Adaptive Biotechnologies Announces Launch Of Clonoseq® To Assess Minimal Residual Disease (Mrd) In Patients With Diffuse Large B-Cell Lymphoma (Dlbcl) Using Circulating Tumor Dna (Ctdna)
U.S. RESEARCH ROUNDUP- Avalonbay Communities, Dominion Energy, PayPal Holdings
Adaptive Biotechnologies Corp reports results for the quarter ended in September - Earnings Summary